Lexaria Bioscience Corp. announced on October 1, 2024, the appointment of Michael Shankman, CPA, as its new Chief Financial Officer, effective immediately. Mr. Shankman joins the executive leadership team, bringing his expertise to the company's financial operations.
This key executive appointment is part of Lexaria's ongoing efforts to strengthen its leadership as it advances its drug delivery platforms. The CFO role is critical for managing financial strategy, reporting, and capital allocation.
Mr. Shankman will play a vital role in guiding Lexaria's financial direction as the company continues its research and development initiatives and pursues commercial opportunities within the pharmaceutical industry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.